Middle East and Africa Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class (Immunosuppressant and Immunomodulators), Route of Administration (Injectable and Oral), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce)

TIPRE00022636 | Pages: 128 | Pharmaceuticals | May 2021 | Type: Regional | Status: Published

Market Introduction

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years.  It is a potentially debilitating disease, causing disruption in communication and coordination functions of the body.

 


Get more information on this report :



Market Overview and Dynamics

The Middle East and Africa multiple sclerosis therapeutics market is expected to reach US$ 2,027.86 million by 2027 from US$ 1,319.08 million in 2019; it is estimated to grow at a CAGR of 5.7% from 2020 to 2027. The growth of the market is attributed to a few key driving factors such as increasing awareness about multiple sclerosis amongst population, and development and launch of innovative products. However, the high cost of the multiple sclerosis treatment hinders the market growth.

Multiple sclerosis (MS) is a chronic disease that affects the brain, spinal cord, and optic nerves. Studies show that there is an increase in the prevalence of multiple sclerosis across the Middle East and African countries.  In recent years, various measures and efforts have been taken to create awareness and educate people regarding neurological diseases, which are facilitating patients to access suitable medications and treatments for such conditions. The Multiple Sclerosis Foundation and affiliated groups have initiated National MS Education and Awareness Month, which is observed in March since 2003 to increase awareness about the disease. The goal of this program is to promote an understanding of Multiple Sclerosis and help the patients in making educated decisions of its treatment. Also, the National MS Society created and launched the “MS Kills Connection > < Connection Kills MS” campaign to connect people suffering from MS, people who treat MS patients, and people who run activities to create a world free of MS. Similarly, several players operating in the multiple sclerosis therapeutics market are developing and launching new products. The strategy of geographic and manufacturing capacity expansion, along with the product launches, helps companies cater to a broad customer base. Such developments and launches of new products are emerging as a key trend in the Middle East and Africa multiple sclerosis therapeutics market.

Middle East and Africa is recording the growing number of COVID-19 cases. The COVID-19 pandemic restricted the research and development activities in countries across the region in 2020. Apart from this, a huge population already face a growing burden of non-communicable diseases like hypertension and diabetes, which is making them more vulnerable to the novel coronavirus. The countries in these regions are highly dependent on pharmaceutical products imported from developed countries. Therefore, massive disruptions in supply chains are hindering the growth of the Middle East and Africa multiple sclerosis therapeutics market.

 

Key Market Segments

The Middle East and Africa multiple sclerosis therapeutics market, by drug class, is bifurcated into immunosuppressant and immunomodulators. The immunomodulators segment held a larger share of the market in 2019, whereas the immunosuppressants segment is anticipated to register a higher CAGR in the market during the forecast period.

The Middle East and Africa multiple sclerosis therapeutics market, by route of administration, is bifurcated into injectable and oral. The injectable segment held a larger share of the market in 2019, and the same segment is anticipated to register a higher CAGR in the market during the forecast period.

Based on distribution channel, the Middle East and Africa multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019. However, the e-commerce segment is estimated to register the highest CAGR in the market during the forecast period.

 

Major Sources and Companies Listed

Some of the primary and secondary sources associated with this report on the Middle East and Africa multiple sclerosis therapeutics market are the Multiple Sclerosis Scientific Research Foundation (MSSRF), World Health Organization (WHO), and Ministry of Health and Prevention (MoHAP).

 

Reasons to buy the report

  • Determine prospective investment areas based on a detailed trend analysis of Middle East and Africa multiple sclerosis therapeutics market over the next years.
  • Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
  • Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
  • Identify the major channels driving the Middle East and Africa multiple sclerosis therapeutics market, providing a clear picture of future opportunities that will help Analyze, resulting in revenue expansion.
  • Channelize resources by focusing on the ongoing programs undertaken by the different countries within the Middle East and Africa multiple sclerosis therapeutics market.

 

MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS THERAPEUTICS MARKET SEGMENTATION

By Drug Class

  • Immunosuppressant
  • Immunomodulators

By Route of Administration

  • Injectable
  • Oral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

By Country

  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East and Africa

Company Profiles

  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • F. HOFFMANN-LA ROCHE LTD
  • Biogen
 

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        Middle East and Africa Multiple Sclerosis Therapeutics Market – By Drug Class

1.3.2        Middle East and Africa Multiple Sclerosis Therapeutics Market – By Route Of Administration

1.3.3        Middle East and Africa Multiple Sclerosis Therapeutics Market – By Distribution Channel

1.3.4        Middle East and Africa Multiple Sclerosis Therapeutics Market – By Country

2.           Multiple Sclerosis Therapeutics Market – Key Takeaways

3.           Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Middle East and Africa Multiple Sclerosis Therapeutics– Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        Middle East and Africa (MEA) – PEST Analysis

4.2.2        Expert Opinions

5.           Multiple Sclerosis Therapeutics Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Growing Prevalence of Multiple Sclerosis (MS)

5.1.2        Rising Funding for Multiple Sclerosis Research

5.2         Market Restraints

5.2.1        High Cost of Multiple Sclerosis Treatment

5.3         Market Opportunities

5.3.1        Increasing Awareness About Multiple Sclerosis

5.4         Future Trends

5.4.1        Development and Launch of Innovative Products

5.5         Impact analysis

6.           Multiple Sclerosis Therapeutics Market – Middle East and Africa Analysis

6.1         Middle East and Africa Multiple Sclerosis Therapeutics Market Revenue Forecast and Analysis

7.           Multiple Sclerosis Therapeutics Market Analysis – By Drug Class

7.1         Overview

7.2         Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)

7.3         Immunosuppressant

7.3.1        Overview

7.3.2        Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

7.4         Immunomodulators

7.4.1        Overview

7.4.2        Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

8.           Multiple Sclerosis Therapeutics Market Analysis – By Route of Administration

8.1         Overview

8.2         Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)

8.3         Injectable

8.3.1        Overview

8.3.2        Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

8.4         Oral

8.4.1        Overview

8.4.2        Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9.           Multiple Sclerosis Therapeutics Market Analysis – By Distribution Channel

9.1         Overview

9.2         Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027

9.3         Hospital Pharmacies

9.3.1        Overview

9.3.2        Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9.4         Retail Pharmacies

9.4.1        Overview

9.4.2        Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9.5         E-Commerce

9.5.1        Overview

9.5.2        E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10.        Multiple Sclerosis Therapeutics Market Analysis and Forecast To 2027 – Middle East and Africa Analysis

10.1      Middle East and Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027

10.1.1     Overview

10.1.2     Middle East and Africa Multiple Sclerosis Therapeutics Market Share, By Country (2019 & 2027) (%)

10.1.3     Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.3.1       Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.3.2       Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)

10.1.3.3       Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)

10.1.3.4       Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)

10.1.4     South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027

10.1.4.1       South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.4.2       South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)

10.1.4.3       South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)

10.1.4.4       South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel US$ Mn)

10.1.5     UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027

10.1.5.1       UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.5.2       UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)

10.1.5.3       UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)

10.1.5.4       UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)

10.1.5.5       Rest of Middle East and Africa: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.        Impact of COVID-19 Pandemic on Middle East and Africa Multiple Sclerosis Therapeutics Market

11.1      Middle East and Africa: Impact Assessment of COVID-19 Pandemic

12.        Industry Landscape

12.1      Overview

12.2      Organic Developments

12.2.1     Overview

12.3      Inorganic Developments

12.3.1     Overview

13.        Company Profiles

13.1      Merck & Co., Inc.

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2      Novartis AG

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3      Bayer AG

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4      Sanofi

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5      Bristol-Myers Squibb Company

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

13.6      TEVA PHARMACEUTICAL INDUSTRIES LTD

13.6.1     Key Facts

13.6.2     Business Description

13.6.3     Products and Services

13.6.4     Financial Overview

13.6.5     SWOT Analysis

13.6.6     Key Developments

13.7      F. HOFFMANN-LA ROCHE LTD.

13.7.1     Key Facts

13.7.2     Business Description

13.7.3     Products and Services

13.7.4     Financial Overview

13.7.5     SWOT Analysis

13.7.6     Key Developments

13.8      Biogen

13.8.1     Key Facts

13.8.2     Business Description

13.8.3     Products and Services

13.8.4     Financial Overview

13.8.5     SWOT Analysis

13.8.6     Key Developments

14.        Appendix

14.1      About The Insight Partners

14.2      Glossary of Terms

LIST OF TABLES

Table 1.             Saudi Arabia Multiple Sclerosis Therapeutic Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)

Table 2.             Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)

Table 3.             Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 4.             South Africa Multiple Sclerosis Therapeutic Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)

Table 5.             South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)

Table 6.             South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 7.             UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)

Table 8.             UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)

Table 9.             UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)

Table 13.          Organic Developments Done By Companies

Table 14.          Inorganic Developments Done By Companies

Table 15.          Glossary of Terms, Multiple sclerosis therapeutics Market

LIST OF FIGURES

Figure 1.           Multiple Sclerosis Therapeutics Market Segmentation

Figure 2.           Multiple Sclerosis Therapeutics Market Segmentation, By Country

Figure 3.           Multiple Sclerosis Therapeutics Market Overview

Figure 4.           Immunomodulators Segment by Drug Class Held the Larger Share of Multiple Sclerosis Therapeutics Market

Figure 5.           Middle East and Africa Multiple Sclerosis Therapeutics Market – Leading Country Markets (US$ Million)

Figure 6.           Middle East and Africa (MEA) PEST Analysis

Figure 7.           Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints

Figure 8.           Middle East and Africa Multiple Sclerosis Therapeutics Market – Revenue Forecast and Analysis – 2019- 2027

Figure 9.           Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)

Figure 10.        Immunosuppressant: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 11.        Immunomodulators: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 12.        Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)

Figure 13.        Injectable: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 14.        Oral: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 15.        Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027

Figure 16.        Hospital Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 17.        Retail Pharmacies: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 18.        E-Commerce: Multiple Sclerosis Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

Figure 19.        Middle East and Africa Multiple Sclerosis Therapeutics Market Share Overview, By Country (2019)

Figure 20.        Middle East and Africa Multiple Sclerosis Therapeutics Market Share, By Country (2019 & 2027) (%)

Figure 21.        Saudi Arabia Multiple Sclerosis Therapeutic Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 22.        South Africa Multiple Sclerosis Therapeutic Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 23.        UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 25.        Impact of COVID-19 Pandemic in Middle East and Africa Market

 

  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • F. HOFFMANN-LA ROCHE LTD
  • Biogen

 

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East and Africa multiple sclerosis therapeutics market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Middle East and Africa multiple sclerosis therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

 

 

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3000
$1800
Site License
$4000
$2400
Enterprise License
$5000
$3000